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Summary The cytotoxicity of methotrexate (MTX) on representative human tumour cell lines (two cell lines
from head and neck carcinomas, two from breast carcinomas, two from osteosarcomas and one lymphoblas-
toid cell line) was evaluated to: (1) examine the optimal time interval between MTX and folinic acid (FA)
administration; (2) determine the critical FA/MTX concentration ratios; and (3) compare the relative effects of
the equimolar mixture d,I-FA and I-FA. The cytotoxic effects of MTX were assessed by the MTT semi-
automated test. For all of the cell lines tested, a significant inverse relationship was noted between the degree
of MTX cytotoxicity reversal and the duration of the time interval between MTX and FA administration.
Overall an 18 -24 h interval between MTX and FA represented a time-threshold after which MTX effects
could not efficiently be reversed by FA in most cell lines. With shorter time intervals between MTX and FA,
MTX cytotoxicity could be partially on even totally reversed by FA; the intensity of reversal varied among the
cell lines tested, and depended on the FA/MTX ratio. Regardless of the interval between MTX and FA,
analysis of the various FA/MTX ratios revealed a significant direct relationship between this ratio and the
percentage of recovery. Presence of the d-form had no influence on the MTX rescue capacity of the I-form;
this suggests that the presence of the d-FA is unlikely to have any significant clinical consequences.
Methotrexate (MTX) chemotherapy is an active treatment in
several malignancies, including head and neck, breast, and
bone tumours, leukaemias and lymphomas (Jolivet et al.,
1983). High-dose MTX is followed by folinic acid (FA)
rescue in order to increase the drug's therapeutic index.
High-dose MTX with FA rescue has been administered in a
wide variety of dosage schedules (Stoller et al., 1977; Bertino,
1981; Rosen et al., 1982; Evans et al., 1983; Jaffe et al.,
1985). Based on these recent studies, FA rescue appears to
vary as a function of the dose used and the time of rescue
initiation after the start of MTX (between 8 to 36 h). As
stressed recently by Ackland and Schilsky (1987), questions
concerning the optimal application of FA rescue remain
unsolved, particularly the interval between MTX and FA
administration, and the dose and duration of FA rescue. This
need is illustrated in the recent report by Browman et al.
(1990) demonstrating in a randomised clinical trial that tox-
icity and the antitumour response were both decreased by
FA when standard doses of MTX were used.
FA is a pharmaceutical preparation consisting of a 50-50
mixture of the natural I-FA and d-FA forms. Pharmaco-
kinetic studies have established that I-FA and d-FA have
considerably different blood kinetics; in particular, d-FA
accumulation is due to the longer half-life of this form than
the I-form (Straw et al., 1984; Newman et al., 1989). This
raises the question of the pharmacological role of the d-form,
which interferes with intracellular activation of MTX by
polyglutamation (Sato & Moran, 1984). The present study
was thus designed to obtain additional information about the
interaction between MTX and FA. The study protocol evalu-
ated MTX cytotoxicity on representative human tumour cell
lines: two cell lines from head and neck carcinomas, two
from breast carcinomas, two from osteosarcomas, and one
lymphoblastoid cell line. Study aims included determination
of the optimal time interval between MTX and FA, identifi-
cation of critical FA/MTX concentration ratios, and compar-




d,I-FA was from Sigma (ref. 36 F 0189, La Verpilliere,
France), I-FA was generously donated by Lederle Labora-
tories (ref. LFP754, Oullins, France). Working solutions
were prepared in 0.9% NaCl and stored at -20°C no longer
than 7 days. MTX was from R. Bellon Laboratories (Neuilly,
France); a working solution of 5.5 10-3 M was prepared in
distilled water and stored at - 20°C. DMEM medium, RPMI
1640 medium, 1-glutamine, and foetal bovine serum (FBS)
were from Gibco (Paisley, UK). Penicillin and streptomycin
were from Merieux (Lyons, France). Transferrin was from
Flow Laboratories (Irvin, UK). The MTT test was perform-
ed with 3-(4-5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT) and DMSO, both from Sigma.
Cell cultures
The eight human tumour cell lines used are described in
Table I. Cells were routinely cultured in a humidified incu-
bator (Sanyo) at 37'C with an atmosphere containing 8%
CO2 in air. The head and neck cancer cell lines and the
osteosarcoma cell lines were grown in DMEM medium sup-
plemented with 10% FBS, penicillin (50,000 IU I1), strepto-
mycin (86 tLM), and 1-glutamine (2 mM). The breast cancer
cell lines were grown in the same medium supplemented with
insulin (0.1jIM) and transferrin (0.64 liM). The lymphoblas-
toid cell line was grown in RPMI 1640 medium supplement-
ed with 10% FBS, penicillin (50,000 IU 1'), streptomycin
(86fLM) and 1-glutamine (2 mM). In brief, cells were grown in
96-well microtitration plates in their respective culture
medium; 24 h later, they were exposed to MTX for 24 h. The
respective initial cellular densities (Table I) were determined
by a preliminary study in order to obtain optimal logarithmic
growth. The MTX concentrations used (Table I) were based
on a previous dose-response study; the values selected were
located around the concentration inhibiting 50% of cell
growth. For each MTX concentration various MTX-FA (d,l
or 1) combinations were tested in parallel at the following
FA/MTX ratios: 0.01, 0.1, 1.0, 10. The commercial mixture
of 50/50 d,l-FA or pure I-FA was added at the following
intervals after initiation of MTX exposure: at the same time
as MTX, 6, 12, 18, 24 h after the start of MTX, or 6 h after
completion of the 24 h MTX exposure. FA was left in the
medium until the end of the experiment, i.e. between 72 and
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Table I Human tumour cell lines investigated
Initial cell
Doubling time density MTX concentrations FA (d,l) concentrations Duration ofdrug
Cell line Tumour type Origin (h) (cell/well) tested (M) tested (m) exposure (h)
CAL 27 Squamous cell CAL 45 7,000 5 10-7, 5 10-6, 5 i0-O 5 10-8-5 10-4 120
carcinoma of the (Gioanni IC 50 = 5.10-7 M, 5.10-7 M
head and neck et al., 1988)
CAL 33 ,, ,, 104 5,000 5 10-6, 5 10-5 5 10-4 5 10-7-5 10-3 144
IC 50 = 7.10-7 M, 4.10-6 M
MCF 7 Breast carcinoma ATCC 41 7,000 5 10-6, 5 10-5, 5 10-4 5 10-7 5 10-3 120
ref HTB22 IC 50 = 2.10-6 M, 1.10-5 M
T 47 D ,, ATCC 93 7,000 5 10-6, 5 10-5, 5 10-4 5 10-7 - 10-3 144
ref HTB133 IC 50 = 5.10-6 M, 5.10-6 M
OS1 Osteosarcoma ATCC 88 2,500 5 10-7 5 10-5 5 10-8_5 10-4 168
ref HTB85 IC 50 = 5.10-7 M
OS2 ,, ATCC 57 6,000 5 10-6, 5 10-5 5 10-7_5 10-4 168
refCRL 1543 IC 50=1.10-6M, 1.10-6M
RPMI Lymphoblast-like ATCC 27 20,000 5 10-7, 5 10-6, 5 10-5 5 10-8-5 10-4 72
ref CCL 156 IC 50 = 5.10-7 M, 5.10-7 M
Keys: CAL: Center A, Lacassagne, Nice, France; ATCC: American TypeCultureCollection, Rockville, MD; IC 50: concentration inhibiting 50%
of the cell growth as compared to controls without drug, two values are given, they were determined at approximately 3 months interval.
168 h depending on the time required for the controls with-
out drugs to reach 90% confluence (Table I).
MCF7
MTX5 x 1O-6M MTX5 x 1O-5M MTX5 x 1O-4M
Evaluation ofcytotoxicity
The cytotoxic effects of MTX were assessed by the MTT
semi-automated test (Carmichael et al., 1987; Twentyman &
Luscombe, 1987) in the 96-well incubating plates. Results
were expressed as the relative percentage of absorbance com-
pared to the controls without drugs. Absorbance was set at
540 nm and measured on a Titertek Twin reader. Each experi-
mental point was determined in sextuplicate. For all experi-
ments, the coefficient of variations were ranged between 3
and 10%. For each time interval between MTX and FA (d,l
or 1) administration and for each condition defined by the
relative FA/MTX concentrations, the percentage of MTX
cytotoxicity reversal (r) was calculated as follows:
r= 100 x (FA (xy) - MTX (x))
100-MTX (x)
FA (xy) = percentage of cell growth compared to con-
trols in the presence of the pair MTX at the concentra-
tion x plus FA at the concentration y.
MTX (x) = percentage of cell growth compared to con-
trols in the presence of MTX only at the concentration
x.
T47D
MTX 5 X 10-6 M MTX 5 x 10-5 M MTX 5 x 10-4 M
11
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MTX-FA Time delay (Hours)
Figure 1 Percentage of MTX cytotoxicity reversal (r %) as a
function of the time interval between MTX and FA for breast
cancer cell lines MCF 7 and T 47 D. 0, FA/MTX: 0.01; 0,
FA/MTX: 0.1; 0, FA/MTX: 1.
CAL 33
MTX5X1O6M MTX 5 x15M MTX 5 x 10-4 M
Results
For all cell lines and all experimental conditions tested,
Figures 1-4 summarise reversal of MTX cytotoxicity as a
function of the time interval between MTX and FA, the
relative FA/MTX concentration ratios, and the respective
initial MTX concentrations. A significant inverse relationship
was observed for all cell lines between the degree of MTX
cytotoxicity reversal and the duration of the time interval
between MTX and FA (Table II). Overall, a 18-24h delay
between MTX and FA was a time-threshold after which
MTX effects could not be efficiently reversed by FA in most
cell lines; this finding was observed for most of the FA/MTX
ratios, even when the FA concentrations were ten times
higher than the MTX concentrations. For shorter time inter-
vals between MTX and FA, MTX cytotoxicity could be
partially or even totally reversed by FA; the intensity of
reversal varied among the cell lines tested, and depended on
the FA/MTX ratio. The cell lines most sensitive to reversal
100
0
0 6 12 18 24 30
MTX 5 x 10-7 M
0 6 12 18 24 30 0 6 12 18 24 30
CAL 27




0 6 12 18 24 30 0 6 12 18 24 30 0 6 12 18 24 30
MTX-FA Time delay (Hours)
Figure 2 Percentage of MTX cytotoxicity reversal (r %) as a
function of the time interval between MTX and FA for head and
neck carcinoma cell lines CAL 33 and CAL 27. 0, FA/MTX: 0.1;
0, FA/MTX: 1; A, FA/MTX: 10.
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MTX 5 x 10-6 M
0 6 12 18 24 30 0 6 12 18 24 30
052
MTX 5 x 1-6 M MTX 5 x 10M
0 6 12 18 24 30 0 6 12 18 24 30
MTX-FA Time delay (Hours)
Figure 3 Percentage of MTX cytotoxicity reversal (r %) as a
function of the time interval between MTX and FA for osteosar-
coma cell lines OSl and OS2. 0, FA/MTX: 0.1; 0, FA/MTX: 1;
A, FA/MTX: 10.
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Figure 4 Percentage of MTX cytotoxicity reversal (r %) as a
function of the time interval between MTX and FA for the
lymphoblastoid cell line. 0, FA/MTX: 0.1; 0, FA/MTX: l; A,
FA/MTX: 10.
by FA were those derived from breast carcinomas; conse-
quently, for these cell lines, the cut-off of 18-24 h was not as
clear. For these cell lines a substantial reversal percentage
was noted when FA was given at the same time as MTX and
with a FA/MTX ratio of 0.01. The osteosarcoma cell lines
presented an intermediary sensitivity to salvage by FA. The
head and neck cell line CAL 27 and the lymphoblastoid cell
line were the least sensitive to reversal of MTX cytotoxicity
by FA; for these cell lines, an FA/MTX ratio of 1 was
necessary to observe any appreciable reversal when both
drugs were given at the same time. Considering the different
FA/MTX ratios, and regardless of the interval between MTX
and FA, a significant direct relationship was noted between
this ratio and the recovery percentage (Table II). The MTX
concentration had a significant influence on the degree of
reversal of MTX cytotoxicity for FA/MTX ratios of0.01 and
0.1 (Table II). In these cases, relatively more FA would have
been required to achieve an equivalent rescue with increasing
MTX concentrations. By contrast, for FA/MTX ratios of 1
and 10, the MTX concentrations used had no significant
effect on the percentage of MTX cytotoxicity reversal.
For all of the experimental conditions tested, Figure 5
illustrates the correlation between cell survival in the presence
of MTX-d,l-FA and in the presence of MTX-1-FA; the con-
centrations in 1-natural forms were identical in each pair.
This figure reveals that the presence of an additive equimolar
concentration of the d-form had no effect on the MTX
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Figure 5 Comparison between the MTX cytotoxicity reversal
induced by the mixture d-l FA and by pure l-FA (all cell lines and
all experimental conditions are included). The represents the
best line of fit: intercept = 2.72, (P< 0.05), slope = 0.960
(P<0.0001), r = 0.940. --- indicate the 95% prediction limits.
Table II Statistical evaluation of results
Significance
Results Parameters tested level
Effect of the time interval Reversal percentages, time
between MTX and FA intervals (all cell lines)
administration on the cellular
cytotoxicity reversal %
Effect of the FA/MTX Reversal percentages, 1.611 E-7
concentration ratio on the FA/MTX ratios 0.01, 0.1, 1 (cell
cellular cytotoxicity reversal % lines T 47 D and MCF 7)
Reversal percentages, 1.110 E-16
FA/MTX ratios 0.1, 1, 10
(all cell lines except T 47 D and
MCF 7)
Effect of the MTX concentration Reversal percentages, MTX
on the cellular cytotoxicity concentrations,
reversal % at equivalent FA/MTX ratios 0.01 3.760 E-3
FA/MTX ratios (only cell lines MCF 7 and T 47 D)
FA/MTX ratios 0.1 (all cell lines) 3.324 E-4
FA/MTX ratios 1 (all cell lines) 0.100, NS
FA/MTX ratios 10 (all cell lines 0.501, NS
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Discussion
The experimental conditions used tended to reduce the un-
avoidable differences between in vitro observations and in
vivo treatment conditions into patients. This was achieved by
the use of human tumour cell lines covering the spectrum of
MTX-sensitive tumours (Jolivet et al., 1983), by selection of a
24 h MTX exposure period and by using MTX and FA
concentrations representative of the clinical context (Stoller et
al., 1977; Straw et al., 1984; Parker et al., 1986; Milano et al.,
1986; Schroder et al., 1987; Borsi & Moe, 1987; Schilsky et al.,
1989). Among the clinically relevant conclusions which can be
drawn from the present study, the optimum time interval
between MTX and FA appears to be around 18-24 h; a
marked reduction in MTX cytotoxicity occurs during shorter
intervals. This observation concurs well with the similar con-
clusions of a comparable study on human osteosarcoma cell
lines (Diddens et al., 1987) and with the data reported by
Sirotnak et al. (1978) in animal tumour models. A minimum
interval of 24 h thus appears advisable between the start of
MTX and initiation of FA rescue to avoid salvage of
tumoural cells in treated patients. Our data also indicate that,
in tumoural cells, MTX rescue by FA is related to the
increase in the FA concentration, regardless of the MTX
concentration considered. This finding is in favour of
minimal FA doses for therapeutic uses and use of minimal
leucovorin rescue during high-dose methotrexate (Stoller et
al., 1979). This finding may explain why patients treated by
standard dose MTX plus FA rescue, exhibited a significantly
lower response rate than those receiving only MTX, in a
randomised placebo-controlled study (Browman et al., 1990).
For an equivalent MTX rescue, Pinedo et al. (1976) and
Diddens et al. (1987) noted that proportionally more FA was
required with higher MTX concentrations. Diddens et al.
(1987) suggested that this metabolic feature might be due to
a high production of MTX polyglutamate facilitated by high
intracellular levels of MTX. Such observations were statis-
tically confirmed in the present study on a larger number of
cell lines. However, the effects of the MTX concentration on
the percentage of cytotoxicity reversal by FA, at a given
FA/MTX ratio, depended on the value of this ratio. Statis-
tical significance was reached only for the lowest ratios (0.01,
0.1) and not for the highest ratios (1, 10). These observations
could be explained by the fact that active membrane trans-
port is exceeded at high MTX extracellular concentrations,
and the drug passively enters tumour cells (Warren et al.,
1978). This unregulated influx should cause a disproportional
intracellular competition between MTX and FA; only
sufficiently high FA/MTX ratios could suppress such MTX
dose-related effects.
Owing to its longer half-life, d-FA tends to accumulate
more than 1-FA in treated patients (Straw et al., 1984; New-
man et al., 1989), and we thus decided to test the effects of
the presence of an equimolar concentrations of d-FA on the
I-FA MTX rescue capacity. An equimolar ratio between
d-FA and I-FA is found between d-FA and active forms of
FA during repeated oral doses of FA in treated patients
(Schilsky et al., 1989). The experimental conditions we used
were thus also representative of the clinical context. Presence
of the d-form had no influence on the MTX rescue capacity
of the 1-form. Bertrand and Jolivet (1989) found that d-FA
failed to interfere with cell growth support or enhancement
of 5-FU cytotoxicity by the 1-isomer in CCRF-CEM cells in
tissue culture experiments. Taken together these results sug-
gest that, in current clinical indications of FA in oncology
for MTX rescue or as a 5-FU cytotoxicity enhancer, the
presence of the d-form is unlikely to have any significant
clinical consequence. Controlled clinical trials comparing the
effects of the administration of d,l-FA versus I-FA should
provide more definitive data.
The authors thank Nancy Rameau for assistance with translation.
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